WRITE for ATol ADVERTISE MEDIA KIT GET ATol BY EMAIL ABOUT ATol CONTACT US
WSI
Asia Time Online - Daily News
             
Asia Times Chinese
AT Chinese



    Greater China
     May 28, 2005
Beijing sets goals for local pharma industry

BEIJING - Beijing will strive to become No 5 nationally in terms of sales revenue in the pharmaceutical industry, No 1 in the sales of medical apparatus and No 3 in biomedicine by the year 2010, officials have decided. To attain these goals, the city will concentrate its efforts on chemical medicine, Chinese medicine, medical apparatuses and biomedicine.

In chemical medicine, priority will be given to research and development (R&D) of lead compounds, the development of such modern drug making technologies as slow-release, controlled release and targeting technologies, and the development of advanced new drugs for treating cardiovascular diseases, cancer, diabetes, immune system disorders, nephrosis and hepatitis.

In traditional Chinese medicine (TCM), emphasis will be put on the development of quality inspection and certification technology; abstraction, separation, refining and micronizing technologies; computer control and engineering of technological processes; active element screening; and slow-release, skin-penetrating and targeting technologies.

Priority for R&D on medical apparatus production will be given to digital medical instruments, digital X-ray machines, digital ultrasonic diagnosing instruments, magnetic resonance imaging equipment, medical linear accelerators, high-grade microwave and radio frequency therapeutic instruments, and biochemical testing instruments.

Lastly, the biomedical industry will focus on R&D for mass production of bio-information, bio-chip and gene therapeutic technologies, and development of such products as bio-chips for diagnosis, cell immunization drugs, monoclonal antibody diagnostic agents, and genetically engineered drugs and vaccines.

The city will help develop two large medical groups, each with an annual sales revenue of more than 10 billion yuan (US$1.2 billion), five large medical groups each with an annual sales revenue of two billion yuan, and 10 groups with an annual sales revenue of one billion yuan.

(Asia Pulse/XIC)

 

 
 

All material on this website is copyright and may not be republished in any form without written permission.
© Copyright 1999 - 2005 Asia Times Online Ltd.
Head Office: Rm 202, Hau Fook Mansion, No. 8 Hau Fook St., Kowloon, Hong Kong
Thailand Bureau: 11/13 Petchkasem Road, Hua Hin, Prachuab Kirikhan, Thailand 77110